Note: Descriptions are shown in the official language in which they were submitted.
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION
TECHNICAL FIELD
s The present invention relates to novel compounds, and therapeutically
acceptable salts
thereof, which inhibit exogenously or endogenously stimulated gastric acid
secretion and
thus can be used in the prevention and treatment of gastrointestinal
inflammatory diseases.
In further aspects, the invention relates to compounds of the invention for
use in therapy; to
processes for preparation of such new compounds; to pharmaceutical
compositions
~o containing at least one compound of the invention, or a therapeutically
acceptable salt
thereof, as active ingredient; and to the use of the active compounds in the
manufacture of
medicaments for the medical use indicated above.
is BACKGROUND ART
Substituted imidazo[1,2-aJpyridines, useful in the treatment of peptic ulcer
diseases, are
known in the art, e.g. from EP-B-0033094 and US 4,450) 164 (Schering
Corporation); from
EP-B-0204285 and US 4,725,601 (Fujisawa Pharmaceutical Co.); and from
publications by
zo J. J. Kaminski et al. in the Journal of Medical Chemistry (vol. 28, 876-
892, 1985; vol. 30,
2031-2046, 1987; vol. 30, 2047-2051, 1987; vol. 32, 1686-1700) 1989; and vol.
34, 533-
541 ) 1991 ).
An imidazo pyridine derivative being substituted in 8-position with 2, 4) 6-
(CH3)3-
is C6H2CH20 is disclosed in EP-B-0033094 and as "Compound No. 49" in Kaminski
et al.,
J. Med. Chem. vol. 28, 876-892, 1985. However, according to the latter
publication, the
said compound did not show favorable characteristics when tested as an
inhibitor of gastric
acid secretion.
3o For a review of the pharmacology of the gastric acid pump (the H+, K+-
ATPase), see Sachs
et al. ( 1995) Annu. Rev. Pharmacol. Toxicol. 35: 277-305.
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
2
DISCLOSURE OF THE INVENTION
s It has surprisingly been found that compounds of the Formula I, which are
substituted
imidazo pyridine derivatives in which the phenyl moiety is substituted with
lower alkyl in
2- and 6-position, are particularly effective as inhibitors of the
gastrointestinal H+, K+-
ATPase and thereby as inhibitors of gastric acid secretion.
~ o In one aspect, the invention thus relates to compounds of the general
Formula I:
R~
R$
~N
CH3
N
X
R2 R3
R4
I
or a pharmaceutically acceptable salt thereof, wherein
~s
R 1 is CHg or CH20H;
R2 is lower alkyl;
R3 is lower alkyl;
R4 is H or halogen;
Zo RS is H, halogen, or lower alkyl;
Xis NH or O.
CA 02280008 1999-08-03
WO 98!37080 PCT/SE98/00275
3
As used herein, the term "lower alkyl" denotes a straight or branched alkyl
group having
from 1 to 6, preferably 1 to 4, carbon atoms. Examples of "lower alkyl"
include methyl,
ethyl, n-propyl, iso-propyl, n-butyl) iso-butyl, sec-butyl, t-butyl and
straight- and branched-
chain pentyl and hexyl. Preferably) "lower alkyl" means methyl, ethyl) n-
propyi, iso-propyl)
n-butyl, iso-butyl, sec-butyl and t-butyl
The term "halogen" includes fluoro) chloro, bromo and iodo.
Both the pure enantiomers) racemic mixtures and unequal mixtures of two
enantiomers are
~o within the scope of the invention. It should be understood that all the
diastereomeric forms
possible (pure enantiomers) racemic mixtures and unequal mixtures of two
enantiomers)
are within the scope of the invention. Also included in the invention are
derivatives of the
compounds of the Formula I which have the biological function of the compounds
of the
Formula I.
is
Depending on the process conditions the end products of the Formula I are
obtained either
in neutral or salt form. Both the free base and the salts of these end
products are within the
scope of the invention.
:o Acid addition salts of the new compounds may in a manner known per se be
transformed
into the free base using basic agents such as alkali or by ion exchange. The
free base
obtained may also form salts with organic or inorganic acids.
In the preparation of acid addition salts, preferably such acids are used
which form suitably
~s therapeutically acceptable salts. Examples of such acids are hydrohalogen
acids such as
hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, aliphatic)
alicyclic, aromatic
or heterocyclic carboxyl or sulfonic acids, such as formic acid, acetic acid,
propionic acid,
succinic acid, giycolic acid, lactic acid) malic acid, tartaric acid, citric
acid, ascorbic acid,
malefic acid, hydroxymaleic acid, pyruvic acid, p-hydroxybensoic acid, embonic
acid,
so methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid)
halogenbensenesulfonic acid, toluenesulfonic acid or naphthalenesulfonic acid.
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
4
Preferred compounds according to the invention are those of the Formula I
wherein R2 is
CH3 or CH2CH3; R3 is CHg or CH2CH3; R4 is H) Br, CI or F; and RS is H, CH3,
Br, Cl or
F, more preferably H, CH3,_or F.
Particularly preferred compounds according to the invention are:
~ 8-(2,6-dimethylbenzylamino)-2,3,6-trimethylimidazo[ 1,2-a]pyridine;
~ 8-(2,6-dimethylbenzylamino)-3-hydroxymethyl-2-methylimidazo[1,2-a]pyridine;
~ 2,3-dimethyl-8-(2,6-dimethyl-4-fluorobenzylamino)imidazo[ 1,2-a]pyridine;
~o ~ 2,6-dimethyl-8-(2,6-dimethylbenzylamino)-3-hydroxymethyl imidazo[ 1,2-
a]pyridine;
~ 2,6-dimethyl-8-(2,6-dimethyl-4-fluorobenzylamino)-3-hydroxymethylimidazo[
1,2-
a]pyridine;
~ 8-(2,6-dimethyl-4-fluorobenzylamino)-2,3,6-trimethyl imidazo[1,2-a]pyridine;
~ 2,3-dimethyl-8-(2,6-dimethyl-4-chlorobenzylamino) imidazo[ 1,2-a]pyridine;
is ~ 2,6-dimethyl-8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethylimidazo[I,2-
aJpyridine;
~ 8-(2,6-diethylbenzylamino)-2,6-dimethyl-3-hydroxymethylimidazo[1,2-
a]pyridine;
~ 8-(2-ethyl-6-methylbenzylamino)-2,3,6-trimethylimidazo[ 1,2-a]pyridine;
~ 8-(2,6-dimethyl-4-fluorobenzyloxy)-3-hydroxymethyl-2-methylimidazo[1,2-
a)pyridine;
Zo ~ 2,6-dimethyl-8-(2,6-dimethylbenzyloxy)-3-hydroxymethylimidazo[ 1,2-
a]pyridine;
~ 2,6-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)-3-
hydroxymethylimidazo[ 1,2-
a]pyridine;
~ 8-(2-ethyl-4.-fluoro-6-methylbenzylamino)- 2,3,6-trimethyl imidazo[ 1,2-a]
pyridine.
zs Preparation
The present invention also provides the following processes A, B, C, D, and fi
for the
manufacture of compounds with the general Formula I.
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
Process A
Process A for manufacture of compounds with the general Formula I comprises
the
following steps:
s
Compounds of the general Formula II
R'
Rs
/ ,N
CH3
~N
X' H
~o wherein X~ is NH2 or OH, and R1 and RS are as defined for Formula I, can be
reacted
with compounds of the general Formula III
Y
Rz R3
4
is wherein R2, R3 and R4 are as defined for Formula I and Y is a leaving
group, such as a
halide, tosyloxy or mesyloxy , to the compounds of the Formula I.
It is convenient to conduct this reaction in an inert solvent, e.g. acetone,
acetonitrile,
dimethoxyethane, methanol) ethanol or dimethylformamide with or without a
base. The
2o base is e.g. an alkali metal hydroxide, such as sodium hydroxide and
potassium hydroxide;
an alkali metal carbonate, such as potassium carbonate and sodium carbonate;
or an
organic amine, such as triethylamin.
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
6
Process B
Process B for manufacture of compounds with the general Formula I) wherein X
is NH,
comprises the following steps:
s
Compounds of the general Formula IV
R~
Rs
~ ~N
CH3
\ N
NHZ
io wherein R1 and RS are as defined for Formula I, can be reacted with
compounds of the
general Formula V
O H
R2 R3
R
V
is wherein R2, R3 and R4 are as defined for Formula I , in the presence of a
Lewis acid e.g.
zinc chloride to the compounds of the Formula VI
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
7
R~
R5
~ ~N
CH3
\ N
N
i
Rz R3
R4
VI
wherein R 1, R2) R3) R4 and RS are as defined for Formula I, whereupon the
compounds of
the general Formula VI are reduced e.g. by using sodium borohydride or
sodiumcyano
s borohydride to compounds of the general Formula I wherein X is NH. The
reactions can be
carried out under standard conditions in an inert solvent e.g. methanol or
ethanol.
Process C
~o Process C for manufacture of compounds with the general Formula I) wherein
RI is
CH20H, comprises the following steps:
Compounds of the general Formula VII
O
O
Rs
~ ~N
CH3
\ N
~s x' VII
wherein X ~ is NH2 or OH and RS are as defined for Formula I) can be reacted
with
compounds of the general Formula III
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
8
Y
R2 R3
4
wherein R2, R3 and R4 are as defined for Formula I and Y is a leaving group,
such as a
halide, tosyloxy or mesyloxy , to the compounds of the Formula VIII
O
;.H3
R~
R4 VIII
wherein R2, R3, R4, RS and X is as defined for Formula I.
~o It is convenient to conduct this reaction in an inert solvent, e.g.
acetone, acetonitrile,
dimethoxyethane, methanol) ethanol or dimethylformamide with or without a
base. The
base is e.g. an alkali metal hydroxide, such as sodium hydroxide and potassium
hydroxide;
an alkali metal carbonate, such as potassium carbonate and sodium carbonate;
or an
organic amine) such as triethylamin.
is
Reduction of compounds of the general Formula VIII , e.g. by using lithium
aluminium
hydride in tetrahydrofuran or ether yields the compounds of the general
Formula I wherein
R ~ is CH20H.
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
9
Process D
Process D for manufacture of compounds with the general Formula I, wherein R~
is
s CH20H and X is NH comprises the following steps:
Compounds of the Formula IX
O
O
Rs
/ ~N
CH3
N
NH2
to
wherein RS is as defined for Formula I, can be reacted with compounds of the
general
Formula V
O H
Rz R3
/
)
4
V
IS
wherein R2, R3 and R4 are as defined for Formula I , in the presence of a
Lewis acid e.g.
zinc chloride to the compounds of the Formula VI
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
lU
O
O
RS
/ ~N
CH3
N
N
R2 R3
R4 X
wherein R2, R3) R4 and RS are as defined for Formula I, whereupon the
compounds of the
general Formula X are reduced e.g. by using sodium borohydride or sodiumcyano
s borohydride to compounds of the general Formula XI
O
R;
NH
R2 R3
R4
XI
wherein R2, R3) R4 and RS are as defined for Formula I. The reactions can be
carried out
io under standard conditions in an inert solvent e.g. methanol or ethanol.
Reduction of compounds of the general Formula XI e.g. by using lithium
aluminium
hydride in tetrahydrofuran or ether yields the compounds of the general
Formula I wherein
R 1 is CH20H and X is NH.
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
11
Process E
. Condensation of compounds of the general Formula XII
s
R5
NHZ
R4 XII
wherein R2, R3) R4) and RS are as defined for Formula I, with a-halocarbonyl
intermediates of the general formula CH3COCH(Z)COOCH2CH3 wherein Z is Br or
Cl, in
io an inert solvent e.g. acetonitrile or ethanol results in formation of
compounds of the
general Formula XIII wherein R2, R3, R4, and RS are as defined for Formula I
0
R5 ~-"'
O
R2 R3
R4 X~
CA 02280008 1999-08-03
WO 98/37080 PCT1SE98/00275
12
Reduction of compounds of the general Formula XIII e.g. by using lithium
aluminium
hydride in tetrahydrofuran or ether yields the compounds of the general
Formula I wherein
R ~ is CH20H and X is O.
Medical use
In a further aspect, the invention relates to compounds of the formula I for
use in therapy,
in particular for use against gastrointestinal inflammatory diseases. The
invention also
io provides the use of a compound of the formula I in the manufacture of a
medicament for
the inhibition of gastric acid secretion, or for the treatment of
gastrointestinal inflammatory
diseases.
The compounds according to the invention may thus be used for prevention and
treatment
is of gastrointestinal inflammatory diseases, and gastric acid-related
diseases in mammals
including man, such as gastritis, gastric ulcer) duodenal ulcer, reflux
esophagitis and
Zollinger-Ellison syndrome. Furthermore, the compounds may be used for
treatment of
other gastrointestinal disorders where gastric antisecretory effect is
desirable, e.g. in
patients with gastrinomas, and in patients with acute upper gastrointestinal
bleeding. They
2o may also be used in patients in intensive care situations, and pre-and
postoperatively to
prevent acid aspiration and stress ulceration.
The typical daily dose of the active substance varies within a wide range and
will depend
on various factors such as for example the individual requirement of each
patient, the route
zs of administration and the disease. In general, oral and parenteral dosages
will be in the
range of 5 to 1000 mg per day of active substance.
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
13
Pharmaceutical formulations
In yet a further aspect, the invention relates to pharmaceutical compositions
containing at
least one compound of the invention, or a therapeutically acceptable salt
thereof, as active
ingredient.
The compounds of the invention can also be used in formulations together with
other active
ingredients, e.g. antibiotics such as amoxicillin.
io For clinical use, the compounds of the invention are formulated into
pharmaceutical
formulations for oral, rectal, parenteral or other mode of administration. The
pharmaceutical formulation contains a compound of the invention in combination
with one
or more pharmaceutically acceptable ingredients. The carrier may be in the
form of a solid,
semi-solid or liquid diluent, or a capsule. These pharmaceutical preparations
are a further
is object of the invention. Usually the amount of active compounds is between
0.1-95% by
weight of the preparation) preferably between 0.1-20% by weight in
preparations for
parenteral use and preferably between 0.1 and 50% by weight in preparations
for oral
administration.
Zo In the preparation of pharmaceutical formulations containing a compound of
the present
invention in the form of dosage units for oral administration the compound
selected may be
mixed with solid) powdered ingredients, such as lactose, saccharose, sorbitol)
mannitol)
starch, amylopectin) cellulose derivatives, gelatin, or another suitable
ingredient, as well as
with disintegrating agents and lubricating agents such as magnesium stearate,
calcium
2s stearate, sodium stearyl fumarate and polyethylene glycol waxes. The
mixture is then
processed into granules or pressed into tablets.
Soft gelatin capsules may be prepared with capsules containing a mixture of
the active
compound or compounds of the invention) vegetable oil, fat, or other suitable
vehicle for
3o soft gelatin capsules. Hard gelatin capsules may contain granules of the
active compound.
Hard gelatin capsules may also contain the active compound in combination with
solid
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
14
powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato
starch, corn
starch, amylopectin, cellulose derivatives or gelatin.
Dosage units for rectal administration may be prepared (i) in the form of
suppositories
which contain the active substance mixed with a neutral fat base; (ii) in the
form of a
gelatin rectal capsule which contains the active substance in a mixture with a
vegetable oil,
paraffin oil or other suitable vehicle for gelatin rectal capsules; (iii) in
the form of a ready-
made micro enema; or (iv) in the form of a dry micro enema formulation to be
reconstituted in a suitable solvent just prior to administration.
~o
Liquid preparations for oral administration may be prepared in the form of
syrups or
suspensions, e.g. solutions or suspensions containing from 0.1 % to 20% by
weight of the
active ingredient and the remainder consisting of sugar or sugar alcohols and
a mixture of
ethanol, water, glycerol, propylene glycol and polyethylene glycol. If
desired, such liquid
~s preparations may contain coloring agents, flavoring agents, saccharine and
carboxymethyl
cellulose or other thickening agent. Liquid preparations for oral
administration may also be
prepared in the form of a dry powder to be reconstituted with a suitable
solvent prior to
use.
zo Solutions for parenteral administration may be prepared as a solution of a
compound of the
invention in a pharmaceutically acceptable solvent, preferably in a
concentration from
0.1 % to 10% by weight. These solutions may also contain stabilizing
ingredients and/or
buffering ingredients and are dispensed into unit doses in the form of
ampoules or vials.
Solutions for parenteral administration may also be prepared as a dry
preparation to by
2s reconstituted with a suitable solvent extemporaneously before use.
The compounds according to the invention can also be used in formulations
together with
other active ingredients, e.g. for the treatment or prophylaxis of conditions
involving
infection by Helicobacter pylori of human gastric mucosa. Such other active
ingredients
3o may be antimicrobial agents, in particular:
~ ~i-lactam antibiotics such as amoxicillin, ampicillin, cephalothin, cefaclor
or cefixime;
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
~ macrolides such as erythromycin, or clarithromycin;
~ tetracyclines such as tetracycline or doxycycline;
~ aminoglycosides such as gentamycin, kanamycin or amikacin;
~ quinolones such as norfloxacin, ciprofloxacin or enoxacin;
s ~ others such as metronidazole, nitrofurantoin or chloramphenicol; or
~ preparations containing bismuth salts such as bismuth subcitrate, bismuth
subsalicylate,
bismuth subcarbonate, bismuth subnitrate or bismuth subgallate.
~o EXAMPLES
1. PREPARATION OF COMPOUNDS OF THE INVENTION
Example 1.1
is
Synthesis of 8-(2,6-dimethylbenrylamino) -2.3,6-trimethylimidazojl,2-
aJpyridine
hydrochloride
CH3
H3C
~N
CH3
W
N
NH x HCI
H3C ~ CH5
zo
A stirred mixture of 8-amino-2,3,6-trimethylimidazo[1,2-aJpyridine (0.9 g, 5.1
mmol),
zinc(II) chloride (0.84 g) 6.2 mmol) and 2,6-dimethylbenzaldehyd (0.83 g, 6.2
mmol) in
methanol (50 ml) was treated with sodium cyanoborohydride (0.39 g, 6.2 mmol)
and was
refluxed for 3 h. The methanol was evaporated under reduced pressure and the
residue was
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
16
dissolved in methylene chloride and 2 M sodium hydroxide (40 ml). The organic
layer was
separated, dried over sodium sulfate and evaporated under reduced pressure.
The residue was purified twice by column chromatography on silica gel, using
a) ethyl
acetate : methyIene chloride ( 1 : 2) and b) methanol : methylene chloride (
1: 20) as eluent.
The oily product was dissolved in diethyl ether) treated with diethyl
ether/HCl and the
precipitated salt was filtered off to give 0.6 g (36%) of the title compound.
1 H-NMR (300 MHz, CDCl3): 8 2.33 (s, 3H), 2.38 (s, 3H)) 2.45 (s, 6H)) 2.50 (s,
3H), 4.40
~o (d) 2H), 6.40 (bs, 1H), 7.95-7.15 (m, 4H).
Example 1.2
~s Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-6-fluoroimidazo (1,2-
aJpyridine
CH3
F
~N
CH3
N
NH
H3C ~ CH3
A stirred mixture of 8-amino-2,3-dimethyl-6-fluoroimidazo[1,2-a]pyridine (0.16
g, 0.89
2o mmol), zinc(II) chloride (0.14 g, 1.04 mmol) and 2,6-dimethylbenzaldehyd
(0.14 g, 1.04
mmol) in methanol (50 ml) was treated with sodium cyanoborohydride (0.065 g)
1.04
mmol) and was refluxed for 7 h. The cooled reaction mixture was added to 0.5 M
NaOH
(20 ml) and the precipitated solids were filtered off and purified by column
chromatography on silica gel) using methanol : methylene chloride ( 1: 10) as
eluent.
zs Crystallization from petroleum ether gave 0.1 g (38%) of the title
compound.
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
17
1H-NMR (300 MHz, CDC13): b 2.30 (s, 3H), 2.34 (s, 3H), 2.40 (s, 6H) 4.35 (d,
2H), 4.95
(bs, 1H), 6.15 (dd, 1H), 7.0-7.20 (m, 4H).
s
Example 1.3
Synthesis of 2,3-dimethyl-8-(2,6-diethylbenrylamino)-imidazo (1,2-aJpyridine
CH3
--CH3
M3
~o
8-amino-2,3-dimethyl-imidazo[1,2-aJpyridine (0.33 g, 2.0 mmol) and 2,6-
diethylbenzaldehyde (0.36 g, 2.2 mmol) were dissolved in methanol (7 m1).
ZnCI? (0.30 g)
2.2 mmoI) and subsequently NaBH3CN (0.14 g, 2.2 mmol) in small portions were
added
is and the mixture was refluxed under argon for 3 hours) cooled and then
poured over an
aqueous 1M NaOH solution ( 10 ml). The resultant yellow suspension was
extracted with
DCM (3x25 ml) and the combined organic solutions were washed with brine, dried
over
Na2S04 and then removed. The oily residue (0.4 g) was purified by flash
chromatography
(DCM-EtOAc 0%-20% EtOAc) to give 0.34 g. Treatment of this oily product with
hexane
20 (2 ml) afforded 0.14 g (23%) as off white crystals.
~ H-NMR (300 MHz, CDCl3): b 7.2-7.3 (2H, m), 7.1 (2H) d), 6.7 ( 1 H, t), 6.2 (
1 H, d), 4.8
(1H, b), 4.4 (2H, d), 2.7 (4H, q), 2.3 (6H) two singlets)) 1.2 (6H) t).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
18
Example 1.4
Synthesis of 8-(2,6-dimethylbenryloxy)-3-hydroxymethyl-2-methylimidazo~l,2-
aJpyridine
i3
A mixture of 8-hydroxy-3-hydroxymethyl-2-methylimidazo[ 1,2-a]pyridine (0.89
g, 5.0
mmol), sodium carbonate ( 1.5 g)) sodium iodide (0.4 g)) 2,6-
dimethylbenzylchloride (0.7 g)
4.5 mmol) and acetone (60 ml) was stirred overnight. More sodium carbonate (
1.0 g) was
~o added. The reaction mixture was refluxed for 2 h. The reaction mixture was
filtered and the
solvent was removed in vacuo. The residue was suspended in CH2Cl2/MeOH (
100:5) and
filtered. Vacuum evaporation of solvent gave a residue which was purified by
flash
chromatography eluting with CH2Ci2-MeOH ( 100:4), collecting fractions, and
recrystallized from CH2Cl2/CH3CN to give 0.37 g of the title compound.
~s
~ H NMR (300 MHz, CDCl3): S 7.87 (d, J=7.6 Hz) 1 H)) 7.15-7.08 (m, 1 H), 7.0
(d, J=7.6
Hz, 2H), 6.73 (t) J=7.6 Hz) 1 H), 6.63 (d, J=7.6 Hz, 1 H), 5.23 (s, 2H), 4.83
(s, 2H), 2.4 (s,
6H), 2.28 (s, 3H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
19
Example 1.5
Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenrylamino)imidazo~l,2-aJpyridine
H3C / CH3
s
A mixture of 8-amino-2,3-dimethylimidazo[1,2-a]pyridine (0.7 g) 4.34 mmol),
sodium
carbonate (2.0 g)) sodium iodide (0.3 g), 2,6-dimethylbenzylchloride (0.671 g,
4.34 mmol)
and acetone (30 ml) was stirred overnight. The reaction mixture was filtered
and the
io solvent was removed in vacuo. The residue was dissolved in methylene
chloride and
washed with aqueous NaHC03. The organic layer was separated and the solvent
was
evaporated. The crude product was purified by flash chromatography eluting
with
CH2C12/MeOH to give 0.7 g of the title compound.
i s 1 H NMR (300 MHz) CDCl3): 8 7.25 (d) J=7.7 Hz, i H)) 7.14-7.09 (m) 1 H),
7.03 (d) J=7.7
Hz, 2H)) 6.73 (t) J=7.7 Hz, 1 H)) 6.21 (d, J=7.7 Hz, 1 H), 4.79 (br "t", 1 H),
4.34 (d, J=4.5
Hz, 2H)) 2.38 (s, 6H)) 2.34 (s, 6H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
Example 1.6
Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzyloxy)imidazo(1,2-ajpyridine
CH3
~ ~N
CH3
N
O
H3C / CH3
s
A mixture of 8-hydroxy-2,3-dimethylimidazo[ 1,2-aJpyridine ( 1.2 g, 7.41
mmol), 2,6-
dimethylbenzylchloride ( 1.145, 7.41 mmol), sodium iodide (0.3 g), sodium
carbonate (2.0
g) and acetone (50 ml) was refluxed for 3 h. After the addition of methylene
chloride the
io reaction mixture was filtered. The solvent was removed in vacuo. The
residue was
dissolved in CH2Cl2, washed with aqueous NaHC03, dried over Na2S04 and
evaporated.
The residue was chromatographed on silica, eluting with CH2Cl2-MeOH ( 100:5)
to give
0.70 g of the desired product (from ethyl acetate-ether).
~s 1H NMR (300 MHz, CDCl3): 8 7.56 (d, J=6.6 Hz) 1H)) 7.I (t, J=6.6 Hz, IH))
6.94-6.85
(m) 3H)) 6.73 (d, J=6.6 Hz, 1H), 2.3I (s, 3H), 2.26 (s, 3H), 2.24 (s, 6H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
21
Example 1.7
Synthesis of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)imidazo[l,2-
a]pyridine.
H3
H3C
S
8-Amino-2,3-dimethylimidazo[ 1,2-a]pyridine (0.3 g, 1.86 mmol) and 2-ethyl-6-
methylbenzylchloride (0.31 g, 1.84 mmol) were dissolved in 5 ml
dimethoxyethane.
Potassium iodide (0.2 g, 1.2 mmol) and Na2C03 (0.3 g, 2.8 mmol) were added and
the
io mixture was refluxed for 4 hours. The solvent was evaporated and the
residue was purified
by column chromatography on silica gel using a mixture of methylene chloride
and ethyl
acetate (60:40) as eluent. 230 mg (42%) of the title compound was obtained.
~ H-NMR (300 MHz, CDC13): S 1.22 (t, 3H), 2.35 (s) 6H)) 2.39 (s, 3H), 2.70 (q,
2H), 4.35
is (d) 2H)) 4.81 (t) 1H), 6.21 (d, 1H)) 6.73 (t) 1H)) 7.01-7.10 (m) 2H), 7.13-
7.19 (m, 1H), 7.24
(d, 1H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
22
Example 1.8
Synthesis of 6-bromo-2,3-dimethyl-8-(2,6-dimethylbenzylamino) imidazo(1,2-
aJpyridine
CH3
Br /
~N
CH3
N
NH
H3C / CH3
s
A mixture of 8-amino-6-bromo-2,3-dimethylimidazo[ 1,2-a]pyridine ( 1.2 g) 5.0
mmoI), 2,6-
dimethylbenzylchloride (0.772 g, 5.0 mmol)) sodium carbonate (0.8 g), sodium
iodide (0.2
g) and acetone (45 ml) was stirred overnight. More 2,3-dimethyIbenzylchloride
(0.285 g)
~o was added and the reaction mixture was refluxed for 5 h. After addition of
acetone the
reaction mixture was filtered. The solvent was removed in vacuo and the
residue was
dissolved in CH2Cl2, washed with NaHCOg, dried over Na2S04 and evaporated. The
crude
product dissolved in ethyl acetate and petroleum ether was added. Filtration
and
evaporation of the solvent gave a residue which was recrystallized from ethyl
acetate to
~s give 1.45 g of the title compound.
~ H NMR (300 MHz) CDCl3): 8 7.37 (d, J= I .5 Hz, 1 H)) 7.1 S-7.09 (m, 1 H))
7.04 (d, J=7.5
Hz, 2H), 6.28 (d) 1=1.5 Hz, 1 H), 4.88 ("t", 1 H). 4.33 (d, J=4.13 Hz, 2H),
2.38 (s, 6H), 2.3
(s, 3H), 2.29 (s, 3H).
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
23
Example 1.9
Synthesis of 8-(2,6-dimethylbenzylamino)-3-hydroxymethyl-2-methylimidazo~l,2-
aJpyridine
s
)H
CH3
H3C / CH3
A solution of vitride (40 ml, 136 mmol) in toluene (25 ml) was added dropwise
to a
nitrogen-purged solution of 3-carboethoxy-8-(dimethylbenzylamino)-2-
methylimidazo[ 1,2-
io a]pyridine (8.0 g, 23.71 mmol) in toluene ( 100 ml). The ice-bath was
removed and the
reaction mixture was stirred at room temperature for 105 min. The reaction
mixture was
cooled to O~C and quenched by addition of water (36 ml). The mixture was
filtered and the
organic layer washed with aqueous NaHC03, dried over Na2S04 and concentrated.
Acetonitrile (20 ml) was added and the product was collected by filtration.
The crystalline
~s product was washed twice with acetonitrile and dried in vacuo. Yield 5.6 g.
~H NMR (300 MHz, CDC13): 8 7.58 (d, J=7.1 Hz, 1H)) 7.15-7.1 (m, 1H), 7.05 (d,
J=7.1
Hz, 2H)) 6.74 (t, J=7.1 Hz) 1 H), 6.28 (d, J=7.1 Hz, 1 H), 4.84 (br t, J=4.5
Hz, 1 H)) 4.8 (s)
2H)) 4.35 {d, J=4.5 Hz, 2H)) 2.4 (s, 6H)) 2.2 (s, 3H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
24
Example 1.10
Synthesis of 6-chloro -2,3-dimethyl-8-(2,6-dimethylbenzylamino)
imidazo~l,2-aJpyridine
s
CH3
A mixture of 8-amino-6-chloro-2,3-dimethylimidazo[ 1,2-a]pyridine (0.894 g,
4.57 mmol),
2,6-dimethylbenzaldehyde (0.77 g, 5.7 mmol),ZnCl2 (1.08 g, 7.92 mmol),
NaB(CN)H3
io (0.36 g, 5.7 mmol) and MeOH (35 ml) was refluxed for 3.5 h. More 2,6-
dimethylbenzaldehyde (0.25 g in 4 ml MeOH), ZnCl2 (0.55 g) and NaB(CN)Hg (0.35
g)
were added. The reaction mixture was refluxed for additional 4 h. Subsequent
workup by
addition of I M NaOH ( 150 ml), and water (SO ml)) followed by extraction of
the mixture
with CH2C12, drying) and evaporation of solvent gave a solid residue. The
crude product
~s dissolved in ethyl acetate and ether was added. Filtration and evaporation
of solvent gave a
residue which was recrystallized from ethyl acetate to give 0.52 g product.
1H NMR (300 MHz, CDC13): S 7.28 (d) J=1.7 Hz, 1H)) 7.15-7.1 (m, 1H)) 7.04 (d,
J=12
Hz, 2H), 6.2 (d, J=1.7 Hz) 1H)) 4.89 (br "t", 1H), 4.33 (d, J=4 Hz, 2H), 2.37
{s, 6H}, 2.33
20 (s) 3H), 2.32 (s, 3H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
Example 1.11
Synthesis of 2,3-dimethyl-8-(2,6-dimethyl-4 fluorobenzylamino)imidazojl,2-
aJpyridine
H3C
CH3
~ ~N
CH3
N
NH
/ CH3
s F
8-Amino-2,3-dimethylimidazo[ 1,2-a]pyridine (0.5 g, 3.1 mmol) was dissolved in
acetonitrile (6 ml). To the solution were added 2,6-dimethyl-4-fluoro-
benzylbromide (0.67
g, 3.1 mmol) and potassium carbonate (0.47g, 3.4 mmol). The mixture was
refluxed for 16
io h. Methylene chloride ( 12 ml) and a sodium chloride solution (20 ml) was
added. The
organic layer was separated, dried over sodium sulfate and evaporated under
reduced
pressure. The crude product was purified by chromatography (ethyl acetate:
petroleum-
ether 1:1 ). 400 mg of the title compound was obtained as a solid.
is ~H-NMR (300 MHz, CDCl3): S 2.3 (s) 6H), 2.3 (s,6H), 4.2 (d,2H)) 4.65
(b,lH)) 6.15 (d)
1H)) 6.65-6.75 (m,3H), 7.2 (d,lH)
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
26
Example 1.12
Synthesis of 2,6-dimethyl-8-(2,6-dimethylbenzylamino)-3-hydroxymethyl
imidazo(1,2-
aJpyridine _
OH
H3C
~N
CH3
N
NH
H3C / CH3
A solution of 3-carboethoxy-2,6-dimethyl-8-(2,6-dimethylbenzylamino) imidazo[
1,2
a]pyridine (0.4 g) 1.1 mmol) in 10 ml toluene was cold with ice- water, Red-AL
65% in
~o toluene (2.1 g, 6.6 mmol) was added after 30 min. The solution was stirred
for 2 h at room
temperature. 10 ml of Rochelle - salt solution (sodium potassium tartrate
tetrahydrate, 35 g
/ 250 ml water) was added dropwise) 10 ml toluene was added, the organic layer
was
separated and washed with water, dried over sodium sulfate and evaporated
under reduced
pressure. The residue was purified by column chromatography on silica gel)
eluent
~s dichloromethane : methanol 9 : 1, to give 0.21 g, (62%) of the title
compound.
1H-NMR (300 MHz, CDC13 ) : 8 1.65 (s, 1H ), 2.30 (d, 6H ), 2.38 (s, 6H)) 4.37
(d) 2H),
4.75 (s, 1H ), 4.85 (s, 2H)) 6.15 (s, 1H )) 7.0 - 7.15 (m, 3H)) 7.40 (s, 1H ).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
27
Example 1.13
Synthesis of 2,6-dimethyl-8-(2,6-dimethyl-4-fluorobenzylamino)-3-
hydroxymethylimidazo~l ,2-a)pyridine
OH
H3C
-N
CH3
~N
NH
H3C / CH3
F
A solution of 0.4 g ( 1.1 mmol) of 3-carboethoxy-2,6-dimethyl-8-(2,6-dimethyl-
4-
fluorobenzylamino)-imidazo[ 1,2-a]pyridine in 10 ml toluene was chilled with
ice-water)
~o (2.1 g, 6.6 mmol). Red-AI 65% in toluene was added after 30 min. The
solution was stirred
for 2 h at room temperature. 10 ml of Rochelle-salt solution, (35 g sodium
potassium
tartrate tetrahydrate / 250 ml water) was added dropwise, 10 ml toluene was
added, the
organic layer was separated) washed with water) dried over sodium sulfate and
evaporated
under reduced pressure.
is The residue was purified by column chromatography on silica gel) eluent
dichloromethane
methanol 95 : 5, to give 0.3 g (83%) of the title copound.
I H NMR (300 MHz, CDC13): b 2.26 (s, 3H)) 2.33 (s, 3H), 2.37 (s) 6H)) 4.28 (d,
2H)) 4.70
(s, 1 H)) 4.82 (s, 2H), 6.14 (s) 1 H), 6.75 (d) 2H), 7.42 (s, 1 H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
28
Example 1.14
Synthesis of 8-(2,6-dimethyl-4 fluorobenzylamino)-2,3,6-trimethylimidaZO(1,2-
aJpyridine
hydrochloride
A stirred mixture of 8-amino-2,3,6-trimethylimidazo[1,2-a]pyridine (0.5 g,
2.85 mmol),
2,6-dimethyl-4-fluorobenzylbromide (0.7 g, 3.4 mmol), potassium carbonate (0.6
g, 4.6
~o mmol), sodium iodide (0.1 g), 15 ml acetonitrile was refluxed over night.
The solvent was
evaporated under reduced pressure and the residue was dissolved in
dichloromethane and
washed with water. The organic layer was dried over sodium sulfate and
evaporated under
reduced pressure. The residue was purified by column chromatography on silica
gel eluent
hexane : ethyl acetate 2:1. The oil product was dissolved in diethyl ether,
treated with
is diethyl ether/HCl and the precipitated salt was filtered off to give 0.55
g) (56%) of the title
compound.
I H NMR (300 MHz) CDCl3): 8 2.22 (s, 3H), 2.30 (d, 12H), 4.23 (d, 2H), 4.68
(s, 1 H), 6.05
(s, 1H), 6.70 (d, ZH), 7.00 (s, 1H).
zo
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
29
Example 1. l S
Synthesis of 2,3-dimethyl-8-(2,6-dimethyl-4-chlorobenzylamino) imidazo[l,2-
a]pyridine.
s
A mixture of 4-chloro-2,6-dimethylbenzylbromide and 2-chloro-4,6-
dimethylbenzylbromide ( 1.1 g, 4.68 mmol) and 8-amino-2,3-dimethylimidazo[ 1,2-
a]pyridine (4.65 mmol) was dissolved in 15 ml dimethoxyethane. Potassium
iodide (0.5 g,
~0 3.0 mmol) and Na2C03 ( 1 g, 9.4 mmol) was added. The mixture was refluxed
for 4 hours.
The solvent was evaporated and the residue was purified by column
chromatography on
silica gel. The product was eluted with a mixture of methylene chloride and
ethyl acetate
(70:30). 70 mg of the title compound was obtained.
is 1H-NMR (300 MHz, CDCl3): 8 2.35 (s) 6H), 4.29 (d, 2H), 4.74 (t) 1H), 6,19
(d, 1H), 6.72
(t, 1H), 7.04 (s) 2H)) 7.25 (d, 1H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
Example 1.16
Synthesis of 2, 6-dimethyl-8-(2-ethyl-6-methylbenrylamino)-3-
hydroxymethylimidaZO(l, 2-
a)pyridine
~3
3-Carboethoxy-2,6-dimethyl-8-(2-ethyl-6-methylbenzylamino~midazo[ 1,2-
a)pyridine ( 1.0
to g 2.8 mmol) was added to tetrahydrofuran (25 ml) and was stirred at
+5°C. Lithium
aluminum hydride (0.5 g, 13 mmol) was added in portions during 1.5 h so that
the
temperature remained below +10°C. After stirring the mixture at room
temperature for an
additional 1 h, 0.5 ml of water was added dropwise, followed by 0.5 ml of 15%
sodium
hydroxide and then 1.5 ml of water. The solids were removed by filtration and
washed
i s thoroughly with tetrahydrofuran and methylene chloride. The filtrate and
washings were
combined and dried and the solvents were removed under reduced pressure. The
residue
was solved in methylene chloride and washed with water. The organic layer was
separated)
dried over sodium sulfate, evaporated under reduced pressure and the residue
was purified
by column chromatography on silica gel using ethylacetate:methylene chloride (
1:1 ) as
Zo eluent. Crystallization from petroleum ether: diethyl ether ( 1:1 ) gave
0.37 g {41 %) of the
title compound
1H-NMR (300 MHz,CDCIg): 8 1.25 (t, 3H), 2.25 (s, 3H)) 2.35 (s, 3H))
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
31
2.40 (s, 3H), 2.70 (q, 2H)) 4.35 (d, 2H), 4.75 (bs, 1 H), 4.80 (s 2H), 6.15
(s) 1 H), 7.05-7.25
(m, 3H)) 7.40 (s, 1H)
Example 1.17
s
Synthesis of 8-(2,6-diethylbenzylamino)-2,6-dimethyl-3-hydroxymethyl
imidazo~l,2-
aJpyridine
OH
H3C
-N
~CH3
N
NH
HaC ~ ~ ~CH3
~o
A solution of 3-carboethoxy-2,6-dimethyl-8-(2,6-diethylbenzylamino)
imidazo[1,2-
a]pyridine ( 1.75 g, 4.6 mmol) in 30 ml tetrahydrofuran was treated with
lithium
aluminiumhydride (0.7 g, 18.5 mmol) at room temperature during 3.5 h. The
reaction was
complete after 4 h and was quenched carefully by dropwise addition of water
(0.7 ml))
~s aqueous sodium hydroxide (0.7 ml) 15%) and again water (2 ml). The mixture
was
extracted with chloroform and the organic layer was concentrated. The residue
was
recrystallized in ethanol and the white crystalline product was filtrated,
washed with diethyl
ether and dried in vacuo) which gave 1.5 g (96 %) yield.
20 ~H-NMR (500 MHz, CDCl3): 8 1.23 (t) 6H), 1.99 (s, 1H)) 2.25 (s, 3H), 2.33
(s, 3H)) 2.73
(q, 4H), 4.34 (d, 2H), 4.80 (s, 3H), 6.13 (s) 1 H), 7.09 (d, 2H), 7.22 (t, 1
H), 7.40 (s, 1 H).
CA 02280008 1999-08-03
WO 98/37080 PC"T/SE98/00275
32
Example 1.18
Synthesis of 8-(2,6-diethylbenzylamino) 2,3,6-trimethylimidazo(1,2-aJpyridine
CH3
NH
H3C ~ ~ ~CH3
A stirred mixture of 8-amino-2,3,6-trimethylimidazo[1,2-a]pyridine (0.5 g) 2.8
mmol), 2,6-
diethylbenzaldehyde (0.7 g, 4.3 mmol) and zinc(II)chloride (0.44 g, 3 mmol) in
50 ml
methanol was treated with sodium cyanoborohydride (0.19 g, 3 mmol) and then
refluxed
io for 20 h. The methanol was evaporated under reduced pressure and the
residue was
dissolved in dichloromethylene and water. The organic layer was separated,
dried over
sodium sulfate and evaporated under reduced pressure. The residue was
chromatographed
on silica gel with dichloromethylene first and then dichloromethyiene:
ethylacetate ( 1:1 )
which yielded 0.42 g of the title compound.
is
1H-NMR (300 MHz) CDCl3) : b 1.25 (t, 6H), 2.28 (s, 3H), 2.30 (s, 3H), 2.33 (s)
3H), 2.71
(q, 4H)) 4.36 (d) 2H), 4.84 (s, 1H), 6.10 (s) 1H), 7.04-7.23 (m) 4H)
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
33
Example 1.19
Synthesis of 8-(2-ethyl-6-methylbenzylamino)-2,3,6-trimethylimidazojl,2-
aJpyridine
CH3
un
CH3
~N
H3C
CH3
s
A stirred mixture of 8-amino-2,3,6-trimethylimidazo[ 1,2-a]pyridine (0.5 g,
2.8 mmol)) 2-
ethyl-6-methylbenzaldehyde (0.45 g, 3 mmol) and zinc(II)chloride (0.4 g,
3mmo1) in 50 ml
methanol was treated with sodium cyanoborohydride (0.19 g, 3 mmol) and
refluxed for 20
~o h. The methanol was evaporated under reduced pressure and the residue was
dissolved in
dichloromethylene and water. The organic layer was separated, dried over
sodium sulfate
and evaporated under reduced pressure. The residue was chromatographed on
silicagel with
dichloromethylene:methanol ( 10:1 ) which yielded 0.28 g (33 %) of the title
compound.
is 1H-NMR (300 MHz, CDCl3): 8 1.22 (t, 3H)) 2.32 (s) 6H), 2,34 (s, 3H)) 2.38
(s) 3H)) 2.72
(q, 2H), 4.33 (d, 2H), 4.77 (s, 1H)) 6.08 (s) 1H), 7.03-7.19 (m, 4H)
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
34
Example 1.20
Synthesis of 8-(2,6-dimethyl-4-fluorobenzyloxy)-3-hydroxymethyl-2-
methylimidazo(1,2-
aJpyridine
s
13
Lithium aluminum hydride (0.31 g 8.4 mmol) was added to tetrahydrofuran {30
ml) and 3
carboethoxy-8-(2,6-dimethyl-4-fluorobenzyloxy)-2-methylimidazo[ I ,2-
a]pyridine ( 1.5 g
~0 4.2 mmol) solved in tetrahydrofuran (30m1) was added dropwise during 30
min. 0.31 ml of
water was added dropwise, followed by 0.31 ml of IS% sodium hydroxide and then
0.93
ml of water. The solids were removed by filtration and washed thoroughly with
methanol:methylene chloride ( 1:1 ). The filtrate and washings were combined
and the
solvents were removed under reduced pressure. The residue was purified by
column
is chromatography on silica gel using methylene chloride:methanol (9:1) as
eluent. Treating
the residue with acetonitrile gave 0.9 g (69 %) of the title compound.
iH-NMR (300 MHz, DMSO-d6): S 2.25 (s, 3H), 2.35 (s, 6H)) 4.85 (d) 2H)) 5.1 (t)
1H), 5.2
(s, 2H), 6.8-7.05 (m, 4H), 7.95 (d, 1H)
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
Example 1.21
Synthesis of 6-bromo-8-(2,6-dimethyl-4 fluorobenzy!amino)-3-hydroxymethyl-2-
methylimidazo jl , 2-aJpyridine
s
OH
Br
~N
--CHs
w
N
NH
H3C / CH3
F
LiBH4 (70 mg) was added in portions and during 4 h to a refluxed solution of 6-
bromo-3-
carboethoxy-8-(2,6-dimethyl-4-fluorobenzylamino)-2-methylimidazo[1,2-
a]pyridine (100
mg, 0.23 mmol) in THF. The reaction mixture was quenched by addition of
diluted HCI
~o and methylene chloride was added. The organic layer was separated, dried
and evaporated
in vacuo. The residue was purified by column chromatography on silica gel,
using
methylene chloride:ethyl acetate ( 100:10) as eluent to give 40 mg (44 %) of
the title
compound.
is ~ H-NMR (300) MHz) CDC13): 8 7.72 (s) 1 h), 6.75 (d, 2h)) 6.35 (s) h)) 4.9
(t, 1 h), 4.8 (s)
2h), 4.3 (d, 2h), 2.35 (s) 6h)) 2.25 (s) 3h).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
36
Example 1.22
Synthesis of 2,6-dimethyl-8-(2,6-dimethylbenryloxy)-3-hydroxymethylimidazo(1,2-
aJpyridine
OH
H3C
~N
~--CHs
N
O
H3C / CH3
\
A mixture of vitride (3 ml, 10.2 mmol) in toluene (3 ml) was added dropwise to
nitrogene-
purged solution of 3-carboethoxy-2,6-dimethyl-8-(2,6-
dimethylbenzyloxy)imidazo[1,2-
a)pyridine (0.68 g, 1.93 mmol) in toluene ( 15 ml). The ice-bath was removed
and the
to reaction mixture was stirred at room temp. For 2 h and 15 min. The reaction
mixture was
cooled to 0°C and quenched by addition of water (6 ml). Methylene
chloride/methanol was
added and the reaction mixture was filtered. The solvent was removed in vacuo
and the
residue was purified by column chromatography on silica gel, using methylene
chloride:methanol ( 100:5) as eluent to give 0.35 g (58%) of the title
compound.
IS
~ H-NMR (300) MHz, CDCIg ): b 7.65 (s, 1 H)) 7.10 (t) 1 H), 7.0 (d, 2H), 6.50
(s, 1 H), 5.2 (s)
2H), 4.8 (s, 2H), 2.4 (s) 6H), 2.35 (s, 3H)) 2.25 (s, 3H).
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
37
Example 1.23
Synthesis of 8-(2,6-dimethyl-4-tluorobenzylamino)-3-hydroxymethyl-2-
methylimidazojl,2-
. aJpyridine
s
OH
~ ~N
CH3
~N
NN
H3C
F
A solution of 0.6 g ( 1.7 mmol) of 3-carboethoxy-8-(2,6-dimethyl-4-
fluorobenzylamino)-2-
methylimidazo[1,2-a]pyridine in 30 ml toluene was cold with ice-water. Red-A1
65% 2.1g
i o (6.6 mmol) in toluene was added during 30 min. The soluton was stirred 1 h
at rt. 25 ml of
Rochelle-salt solution, (35 g sodium potassium tartrate tetrahydrate / 250m1
water ) was
added dropwise and the organic layer was separated . The water layer was
washed with
methylene chloride which was separated. The combined organic solvents were
dried over
sodium sulfate and evaporated under reduced pressure. The resiude was purified
by column
~s chromatography on silica gel, eluent dichloromethane : methanol 95 : S,to
give 0.42 g,
(79%) of the title compound.
IH-NMR (300) MHz, CDC13): b 2.15 (s) 3H), 2.35 (s) 6H), 4.30 (d) 2H),
4.75 (s, 2H)) 4.85 (t, 1H)) 6.25 (d, 1H), 6.70-6.80 (m, 3H), 7.55 (d, 1H)
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
38
Example 1.24
Synthesis of 2,6-dimethyl-8-(2-ethyl-4 fluoro-6-methylbenzylamino)-3-
hydroxymethylimidazo(1,2-aJpyridine
s
OH
H3C
-N
W--CH3
N
CH3
To a mixture of LiAlH4 (0.08 g, 2.1 mmol) in tetrahydrofuran ( 15 ml) was
added 3-
carboethoxy-2,6-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)imidazo[ 1,2-
io aJpyridine (0.4g, 1.0) mmol in tetrahydrofuran ( 15 ml). After stirring the
mixture at room
temperature for 4 h. , 0.1 ml of water was added dropwise, followed by 0.1 ml
of 15%
sodium hydroxide and then 0.3 ml of water. The solids were removed by
filtration and
washed thoroughly with tetrahydrofuran. The filtrate and washings were
combined and
dried and the solvent was removed under reduced pressure. The residue was
purified by
is column chromatography on silica gel using methylene chloride: methanol
(9:1) as eluent.
Crystallization from acetonitril gave 0.32 g (89%) of the title compound
~ H-NMR (300 MHz, CDCl3): 8 1.2 (t) 3H), 2.2 (s, 3H), 2.35 (s, 3H), 2.4 (s,
3H), 2.75 (q)
2H), 4.3 (d, 2H), 4.75 (bs, 3H), 6.15 (s, 1H), 6.75-6.85 (m) 2H), 7.45 (s,
1H).
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
39
Example 1.25
Synthesis of 8-(2-ethyl-4 fluoro-6-methylbenzylamino)- 2,3,6-trimethyl
imidazo[1,2-a]
pyridine
s
CH3
H3C
~N
-CH3
\ ~'
N
niu
H3C
CH3
8-Amino-2,3,6-trimethylimidazo[ 1,2-a]pyridine (0.38 g, 2.16 mmoI) and 2-ethyl-
4-fluor-6-
methylbenzylbromide (0.50 g, 2.16 mmol) were dissolved in 10 ml
dimethoxyethane.
io Potassium iodide (0.2 g, 1.2 mmol) and Na2C03 (0.4 g, 3.8 mmol) were added
and the
mixture was refluxed for 6 hours. The solvent was evaporated and the residue
was purified
by column chromatography on silica gel using a mixture of methylene chloride
and ethyl
acetate (60:40) as eluent. 203 mg (29%) of the title compound was obtained.
is ~H-NMR (300 MHz, CDCl3): d 1.21 (t, 3H), 2.32 (s, 6H), 2.33 (s, 3H), 2.37
(s, 3H), 2.71
(q) 2H), 4.28 (d, 2H), 4.68 (t, 1 H), 6.06 (s, 1 H), 6.73-6.80 (m) 2H), 7.05
(s) 1 H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
Example 1.26
Synthesis of 2,3-dimethyl-8-(2,6-dimethyl-4 fluorobenzyloxy)imidazo(1,2-
aJpyridine
s
CH3
~ ~N
CH3
~N
O
H3C / CH3
F
2,3-Dimethyl-8-hydroxyimidazo[ 1,2-a]pyridine ( 1.7 g, 10 mmol), 2,6-dimethyl-
4-
fluorobenzylbromide (2.3 g, 10 mmol)) sodium iodide (0.5 g) 0.3 mmol) and
sodium
carbonate (2.6 g, 28 mmol) were added to acetone (75 ml) and the mixture was
refluxed for
io 6 h. Methylene chloride was added and the mixture was filtered and the
solvents were
evaporated under reduced pressure. Purification by column chromatography on
silica gel
using methylene chloride: ethylacetate( 1:2) as eluent gave the title compound
as a white
powder. (0.85 g, 28%)
i s ~ H-NMR (300 MHz, CDC13): d 2.36 (s, 3H)) 2.38 (s) 9H}, 5.15 (s, 2H), 6.57
(d) 1 H), 6.68-
6.75 (m, 3H), 7.46) (d, 1H).
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
41
Example 1.27
Synthesis of 2,3-dimethyl-8-(2-ethyl-6-methylbenryloxy)imidazo(1,2-a jpyridine
CH3
CH3
~N
CH3
s
2,3-Dimethyl-8-hydroxyimidazo[ 1,2-a]pyridine (0.8 g) 5 mmol), 2-ethyl-6-
methylbenzyl
chloride) sodium iodide (0.25g, 1.7 mmol) and sodium carbonate ( 1.2 g) 11
mmol) were
added to acetone (40 ml) and the mixture was refluxed for 5 h. The acetone was
evaporated
~o and the residue was solved in methyiene chloride and washed with water. The
organic
solvent was dried and was evaporated under reduced pressure. The residue was
purified
twice by column chromatography on silica gel using (a) methylene chloride:
ethylacetate( 1:2)) (b) methylene chloride: ethylacetate(2:1 ), as eluent to
give the title
compound. (0.02 g, 1.4%)
~s
t H-NMR (300 MHz) CDCl3): b 1.2 (t) 3H), 2.36 (s, 3H), 2.38 (s) 3H), 2.40 (s,
3H), 2.74 (q,
2H), 5.2I (s, 2H), 6.59 (d, 1H), 6.7 (t, 1H), ?.04 (m, 2H), 7.I7 (t) IH), 7.45
(d, IH).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
42
Example 1.28
Synthesis of 8-(2-ethyl-6-methylbenzyloxy)-3-hydroxymethyl-2-methylimidazo(1,2-
a Jpyridine
s
'7H
CH3
To a mixture of LiAlH4 (0.08 g, 2.I mmol) in tetrahydrofuran (25 ml) was added
3-
carboethoxy-8-(2-ethyl-6-methylbenzyloxy}-2-methylimidazo[ 1,2-a]pyridine (
1.0 g, 2.8
~o mmol) in tetrahydrofuran (25m1). After stirring the mixture at room
temperature for 2 h.,
0.2 ml of water was added dropwise, followed by 0.2 ml of 15% sodium hydroxide
and
then 0.6 ml of water. The solids were removed by filtration and the solvent
was removed
under reduced pressure. The residue was purified by column chromatography on
silica gel
using methylene chloride: methanol (9:1 ) as eluent. Crystallization from
diethyl ether gave
is 0.52 g (60%) of the title compound.
1 H-NMR (300 MHz, CDC13): b 1.2 (t) 3H), 2.25 (s, 3H), 2.4 (s, 3H), 2.75 (q,
2H)) 4.75 (s,
2H), 5.2 (s, 2H}) 6.65-6.75 (m, 2H), 7.0-7.2 (m, 3H), 7.85 (d, IH).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
43
TABLE 1
Summary of the compounds according to Examples 1.1 to 1.28
Example Rl R2 R3 R4 RS X
1.1 CH3 CH3 CH3 H CH3 NH
1.2 CH3 CH3 CH3 H F NH
1.3 CH3 CH2CH3 CH2CH3 H H NH
1.4 CH20H CH3 CH3 H H O
1.5 CH3 CH3 CH3 H H NH
1.6 CH3 CH3 CH3 H H O
1.7 CH3 CH3 CH2CH3 H H
1.8 CH3 CH3 CH3 H Br NH
1.9 CH20H CH3 CH3 H H NH
1.10 CH3 CH3 CH3 H Cl NH
1.11 CH3 CH3 CH3 F H NH
1.12 CH20H CH3 CH3 H CH3 NH
1.13 CH20H CH3 CH3 F CH3 NH
1.14 CH3 CH3 CH3 F CH3 NH
1.15 CH3 CH3 CH3 CI H NH
1.16 CH20H CH3 CH2CH3 H CH3 NH
1.17 CH20H CH2CH3 CH2CH3 H CH3 NH
1.18 CH3 CH2CH3 CH2CH3 H CH3 NH
1.19 CH3 CH3 CH2CH3 H CH3 NH
1.20 CH20H CH3 CH3 F H O
1.21 CH20H CH3 CH3 F Br NH
1.22 CH20H CH3 CH3 H CH3 O
1.23 CH20H CH3 CH3 F H NH
1.24 CH20H CH3 CH2CH3 F CH3 NH
1.25 CH3 CH3 CH2CH3 F CH3 NH
1.26 CH3 CH3 CH3 F H O
1.27 CH3 CH3 CH2CH3 H H O
1.28 CH20H CH3 CH2CH3 H H O
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
44
PREPARATION OF INTERMEDIATES
Example 2.1
s Synthesis of 2,6-dimethyl-4-fluorobenzylbromide
A mixture of 3,5-dimethyl-fluorobenzene (5 g, 0.04 mol)) paraformaldehyde ( 15
g))
hydrobromic acid (70 ml) (30% in acetic acid) and acetic acid (25 ml) was
stirred at
ambient temperature for 4.5 h. To the mixture were water and petroleum ether
added and
~o the organic layer was separated dried over anhydrous sodium sulfate and
evaporated
carefully under reduced pressure. The residue was purified by column
chromatography on
silica gel with petroleum ether as eluent to give the desired product. (3.7 g,
43%)
tH-NMR (300 MHz, CDC13): 8 2.5 (s, 6H), 4.55 (s, 2H), 6.75 (d, 2H)
is
Example 2.2
Synthesis of 2-ethyl-6-methylbenrylchloride
20 2-Ethyl-6-methylbenzylalkohol ( 1.0 g, 6.67 mmol) was dissolved in 10 ml
methylene
chloride. Thionyl chloride ( 1.0 g, 8.5 mmol) was added. The mixture was
stirred over night
at ambient temperature. The reaction mixture was evaporated. The residue was
dissolved in
methylene chloride and filtered through 5 g of silica gel. The filtrate was
evaporated. 1.0 g
(89 %) of the title compound (oil) was obtained.
1H-NMR (300 MHz, CDC13): 8 1.29 (t) 3H), 2,46 (s, 3H), 2.76 (q, 2H), 4.71 (s,
2H), 7.0-
7.2 (m) 3H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98100275
Example 2.3
Synthesis of 8-amino-2,3,6-trimethylimidazo~l,2-ajpyridine
s To a solution of 2,3-diamino-5-methylpyridine (2.0 g, 16 mmol) in ethanol (
100 ml) was
added 3-bromo-2-butanon (2.4 g) 16 mmol). The reaction mixture was refluxed
for 16 h.
An additional amount of 3-bromo-2-butanon ( 1.0 g 6.7 mmol) and triethylamine
( 1.0 g, 9.9
mmol) were added and the mixture was refluxed for 2 h. The ethanol was
evaporated under
reduced pressure and the residue was treated with methylene chloride and a
solution of
~ o bicarbonate. The organic layer was separated, dried over sodium sulfate
and evaporated
under reduced pressure. The oily residue was purified by column chromatography
on silica
gel) using methanol : rnethylene chloride ( 1: 20) as eluent to give the
desired product ( 1.05
g, 37%).
is tH-NMR (300 MHz) DMSO-d6): 8 2.15 (s, 3H)) 2.25 (s) 3H), 2.3 (s, 3H), 5.45
(bs, 2H),
6.05 (s, 1H), 7.20 (s, 1H).
Example 2.4
2o Synthesis of 2-amino-S fluoro-3-nitropyridine
To a solution of 2-amino-5-fluoropyridine (8.6 g, 77 mmol) in conc. sulfuric
acid (40 ml)
was added dropwise (30 min) fuming nitric acid (3.25 ml) 77 mmol) at a
temperature of
+3 °C. The reaction mixture was stirred at room temperature for 1 h and
at +55°C for 1 h.
zs The mixture was poured onto ice and neutralized with 10 M sodium hydroxide
and was
extracted with methylene chloride. The organic layer was separated, dried over
sodium
sulfate and evaporated under reduced pressure. The residue was purified twice
by column
chromatography on silica gel, using (i) methanol : methylene chloride ( 1:20)
and (ii)
diethyl ether : petroleum ether ( 1:1 ) as eluent to give the title compound
(0.44 g, 3.6%).
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
46
1H-NMR (300 MHz, CDCI3): S 6.65 (bs, 2H), 8.20 (dd, 1H), 8.35 (d, 1H)
Example 2.5
s Synthesis of 2,3-diamino-5-fluoropyridine
To a solution of 2-amino-5-fluoro-3-nitropyridine (0.42 g) 2.3 mmol) and iron
powder ( 1.6
g, 28 mmol) in ethanol ( 10 ml) were added water (0.5 ml, 28 mmol) and
hydrochloric acid
(27 ~tl, 0.32 mmol). The mixture was refluxed for 1 h. An additional amount of
iron
~o powder (0.2 g, 3.6 mmol) was added and the mixture was refluxed for 30 min.
The reaction
mixture was filtered through celite and evaporation under reduced pressure of
the solvent
gave 0.3 g ( 100%) of the desired product.
1H-NMR (300 MHz) CDCI3): b 3.55 (bs) ZH), 4.1 (bs, 2H), 6.7 (dd, 1H), 7.5 (d,
1H).
Is
Example 2.6
Synthesis of 8-amino-2,3-dimethyl-6-fluoroimidazojl,2-aJpyridine
Zo A mixture of 2,3-diamino-5-fluoropyridine (0.3 g, 2.4 mmol) and 3-bromo-2-
butanon (0.36
g, 2.4 mmol) in ethanol (20 ml) was refluxed for 10 h. The solvent was
evaporated under
reduced pressure. The residue was dissolved in methylene chloride and was
treated with a
bicarbonate solution. The organic layer was separated, dried over sodium
sulfate and
evaporated under reduced pressure. The residue was purified with column
chromatography
2s on silica gel with methanol : methylene chloride ( 1: 20) as eluent to give
0.16 g (37%) of
the title compound.
~H-NMR (300 MHz, CDCl3): 8 2.3 (s, 3H), 2.4 (s, 3H), 4.6 (bs, 2H)) 6.2 (dd,
1H); 7.2 (dd,
1 H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
47
Example 2.7
Synthesis oj8-amino-6-bromo-2,3-dimethylimidazojl,2-aJpyridine
s A solution of 2,3-diamino-5-bromopyridine (4.0 g, 21.29 mmol) and 3-bromo-2-
butanone
(3.7 g, 24.48 mmol) in ethanol (40 ml) was refluxed overnight. After cooling
to room
temperature, the crystalline product was filtered and washed with ethanol and
ether. The
crystals were dissolved in methylene chloride and neutralized by aqueous
NaHC03. The
organic layer was separated, dried over Na2S04 and evaporated in vacuo. Yield
2.3 g.
io
~ H NMR (300 MHz) CDC13): 8 7.39 (d) J=1.7 Hz, 1 H), 6.36 (d, J=1.7 Hz, 1 H),
4.5 (br s,
2H), 2.35 (s, 3H), 2.3 (s, 3H).
Example 2.8
is
Synthesis of 3-carboethoxy-8-(dimethylbenrylamino)-2-methylimidazojl,2-
ajpyridine
A mixture of 8-amino-3-carboethoxy-2-methylimidazo[ 1,2-a]pyridine (6.08 g,
27.74
mmol)) 2,6-dimethylbenzylchloride (4.5 g, 29.13 mmol), sodium carbonate (4.32
g, 43.7
zo mmol), sodium iodide (0.7 g) and acetone ( 120 ml) was stirred for 30 h and
the crystalline
product was filtered off. The yield was dissolved in dichloromethane filtered
and the
solvent was evaporated under reduced pressure to give the title product ( 7.0
g).
~ H NMR (300 MHz, CDC13) 8 8.66 (d, J=11 Hz, 1 H), 7.16-7.1 (m) 1 H), 7.05 (d)
J=11 Hz)
zs 2H)) 6.87 ( t, J=11 Hz, 1 H), 6.45 (d) J=11 Hz) 1 H), 4.86 ("t", 1 H), 4.4
(q) J=7 Hz, 2H), 4.35
(d, J=3.6 Hz, 2H), 2.65 (s, 3H), 2.35 (s, 6H), 1.4 (t) J=7 Hz, 3H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
48
Example 2.9
Synthesis of 8-amino-6-chloro-2,3-dimethylimidazo(1,2-aJpyridine
s A mixture of 2,3-diamino-5-chloropyridine (5.26 g, 36.64 mmol) and 3-bromo-2-
butanone
(6.2 g, 41.06 mmol) in ethanol (60 ml) was refluxed overnight. After cooling
to room
temperature, the crystalline product was filtered and washed with ethanol and
ether. The
crystals were dissolved in methylene chloride and neutralized by aqueous
NaHC03. The
organic layer was separated, dried over Na2S04 and evaporated in vacuo. Yield
3:0 g.
~o
1 H NMR (300 MHz, CDCl3 ): S 7.29 (d, J=1.5 Hz, 1 H), 6.26 (d, J=1.5 Hz, 1 H),
4.55 (br s,
2H)) 2.4 (s) 3H), 2.3 (s, 3H).
Example 2.1 D
~s
Synthesis of 8-amino-3-carboethoxy-2,6-dimethylimidazo(1,2-aJpyridine
A stirred mixture of 2,3-diamino-5-methyl-pyridine (4.0 g) 32.5 mmol) and (5.9
g, 36.0
mmol) of ethyl - chloroacetoacetate in 75 ml abs. ethanol was refluxed over
night. The
zo ethanol was evaporated under reduced pressure. The residue was dissolved in
2 M HCl
and washed 3 times with diethyl ether, pH was adjusted to 9 and extracted 3
times with
dichloromethane. The organic layer was dried over anhydrous sodium sulfate and
evaporated. The residue was purified by column chromatography on silica gel
with
dichloromethane : methanol 95 : 5 as eluent to give the title product 2.0 g
(28%).
1H-NMR (300 MHz) CDC13) : S 1.42 (t, 3H), 2.28 (s, 3H), 2.65 (s, 3H), 4.40 (q)
2H), 4.47
(s, 2H), 6.40 (s, 1H), 8.55 (s, 1H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
49
Example 2.11
Synthesis of 3-carboethoxy-2,6-dimethyl-8-(2,6-dimethylbenzylamino)
imidazo(1,2-
aJpyridine
s
A stirred mixture of 8 -amino-2,6 dimethylimidazol [1,2-a]pyridine
( 1.2 g) 5.1 mmol), zinc(II)chloride (0.84 g, 6.2 mmol) and 2,6 -
dimethylbenzaldehyde
(0.84 g, 6.2 mmol) in 50 mi methanol was treated with sodium cyanoborohydride
(0.39 g)
6.2 mmol) and was refluxed for 5 h. The methanol was evaporated under reduced
pressure
io and the residue was dissolved in dichloromethane and 40 ml 2 M sodium
hydroxide. The
organic layer was separated, dried over sodium sulfate and evaporated under
reduced
pressure. The residue was purified by column chromatography on silica gel)
eluent
petroleum ether (40 - 60) : isopropyl ether 8:2) in yield of 0.8 g, (44%) of
the title
compound.
is
~H-NMR (300 MHz, CDC13): b 1.44 (t, 3H)) 2.35 (d) 9H)) 2.60 (s, 3H), 4.33 (d)
2H), 4.40
(q, 2H), 4.6 (s, 1 H)) 6.60 (s, 1 H), 7.10 (d) 2H), 7.25 (m) 1 H), 8.50 (s, 1
H).
Example 2.12
Zo
Synthesis of 3-carboethoxy-2,6-dimethyl-8-(2,6-dimethylbenzylamino)
imidazo~l,2-
a)pyridine
A stirred mixture of 8 -amino-2,6 dimethyIimidazol [1,2-a]pyridine
2s ( 1.2 g, 5.1 mmol), zinc(II)chloride (0.84 g, 6.2 mmol) and 2,6 -
dimethylbenzaldehyde
(0.84 g, 6.2 mmoi) in 50 ml methanol was treated with sodium cyanoborohydride
(0.39 g,
6.2 mmol) and was refluxed for 5 h. The methanol was evaporated under reduced
pressure
and the residue was dissolved in dichloromethane and 40 ml 2 M sodium
hydroxide. The
organic layer was separated, dried over sodium sulfate and evaporated under
reduced
3o pressure. The residue was purified by column chromatography on silica gel,
eluent
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
petroleumether (40 - 60) : isopropylether 8:2, in yield of 0.8 g) (44%) of the
title
compound.
~ H-NMR (300 MHz, CDCI-3): 8 I .44 (t, 3H), 2.35 (d, 9H), 2.60 (s, 3H), 4.33
(d, 2H), 4.40
s (q) 2H), 4.6 (s, I H), 6.60 (s, 1 H), 7. I O (d, 2H), 7.25 (m, I H)) 8.50
(s, 1 H).
Example 2.13
Synthesis of 3-carboethoxy-2,6-dimethyl-8-(2,6-dimethyl-4-fluorobenzylamino)-
to imidazo(1,2-aJpyridine.
A stirred mixture of ( 1. I g, 4.7 mmol) 8-amino-3-carboethoxy-2,6-
dimethylimidazo[ 1,2-
a]pyridine ( 1.2g, 5.7 mmoi) 2,6-dimethyl-4-fluorobenzylbromide, ( 1.0 g, 7.5
mmol)
potassium carbonate and (0.1 g} sodium iodide in 15 ml acetonitrile was
refluxed over
is night. After evaporation of the solvent under reduced pressure the residue
was dissolved in
dichloromethane and washed with water, the organic layer was separated dried
over sodium
sulfate and evaporated under reduced pressure. The residue was purified by
column
chromatography on silica gel, eluent petroleum ether (40-60) : isopropyl ether
7:3 to give
0.8 g, (47%) of the title compound.
~ H-NMR (300 MHz, CDC13): 8 1.42 (t, 3H), 2.36 (s, 9H)) 2.62 (2, 3H), 4.45 (d,
2H), 4.48
(q, 2H), 4.54 (s) 1 H), 6.30, (s) 1 H), 6.75 (d, 2H)) 8.55 (s, 1 H).
Example 2.14
xs
Synthesis of 4-chloro-2,6-dimethylbenrylbromide.
4-Chloro-3,5-dimethylbenzene ( 1.42 g) 0.01 mol) and parafortnaldehyde (0.31
g, 0.01 mol)
were added to 2 ml of hydrogenbromide (33%) in acetic acid. The mixture was
stirred over
so night at +70°C. The reaction mixture was poured on 25 m1 water and
the product was
extracted with diethyl ether. The organic layer was washed with water. The
organic layer
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
S1
was dried (Na 2S04) and evaporated. 1.1 g product (oil) was obtained. The ~H-
NMR
spectrum shows that the substance was a mixture of the title compound and 2-
chloro-4,6-
dimethylbenzylbromide. The product was used as such without any further
purification in
the next synthetic step (Example 1.15).
s
~H-NMR (300 MHz, CDCl3): 8 2.28 (s, 6H), 4.51 (s, 2H), 7.04 (s) 2H).
Example 2.15
~o Synthesis of 3-carboethoxy-2,6-dimethyl-8-(2-ethyl-6-methylbenzylamino)-
imidazojl,2-
a Jpyridine
A mixture of 8-amino-3-carboethoxy-2,6- dimethylimidazo[ 1,2-a]pyridine ( 1.4
g, 6
mmol)) 2-ethyl-6-methylbenzaldehyde (0.9 g) 6.5 mmol), ZnCl2 ( 1.0 g, 7.4
mmol),
~s NaB(CN)H3 (0.41 g, 6.5 mmol) and MeOH (30 ml) was refluxed for 5 h. More
ZnCl2 (0.2
g) and NaB(CN}H3 (0.1 g) were added. The reaction mixture was refluxed for
additional 2
h. Triethylamin (2 ml) was added and the mixture was stirred at R.T for 10
min. The
solvent was evaporated under reduced pressure and the residue was purified by
column
chromatography on silica gel using methylene chloride as eluent. 1.1 g {50%)
of the title
2o compound was obtained.
~H-NMR (300 MHz, CDCIg): S 1.25 (t) 3H), 1.45 (t, 3H), 2.30 (s, 6H), 2.6 (s,
3H)) 2.75 (q,
2H), 4.35 {d, 2H), 4.45 (q, 2H)) 4.85 (bs) 1 H), 6.35 (s, 1 H), 7.0-7.25 (m,
3H), 8.5 (s, 1 H)
zs Example 2.16
Synthesis of 3-carboethoxy-2,6-dimethyl-8-(2,6-diethylbenzylamino) imidazojl,2-
aJpyridine
so A stirred mixture of 8-amino-3-carboethoxy-2,6-dimethylimidazo[ 1,2-
a]pyridine (2.02 g)
8.6 mmol), zinc(II)chloride ( 1.48 g, 10.8 mmol) and 2,6-diethylbenzaldehyde
(2.17 g, 13.4
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
52
mmol) in SO ml methanol was treated with sodium cyanoborohydride (0.65 g, 10.3
mmol)
and was refluxed overnight. The mixture was allowed to cool and then poured
over 80 ml
1M sodium hydroxide. The precipitate formed was fiitrated and washed with
water and
then purified by column chromatography on silica gel with
dichloromethane:methanol
s (95:5) as eluent. The yield was 2.1 g (64 %) of the title compound.
1H-NMR (500 MHz, CDCl3): 8 1.23 (t, 6H), 1.42 (t, 3H), 2.38 (s, 3H)) 2.61 (s,
3H), 2.72
(q, 4H), 4.34 (d, 2H), 4.40 (q, 2H), 4.83 (t, 1 H), 6.32 (s) 1 H), 7.11 (d,
2H), 7.24 (t) 1 H),
8.51 (s, 1H).
io
Example 2.17
Synthesis of 3-carboethoxy-8-(2,6-dimethyl-4 fluorobenryloxy)-2-
methylimidazo~l,2-
aJpyridine
is
A mixture of 3-carboethoxy-8-hydroxy-2-methylimidazo[1,2-a]pyridine (1.5 g,
6.8 mmol),
2,6-dimethyl-4-fluorobenzylbromide ( 1.6 g, 7.5 mmol), sodium iodide (0.1 g),
potassium
carbonate ( 1.9 g) 13.6 mmol) and acetonitrile (50 ml) was refluxed for over
night.. The
solvent was removed in vacuo. The residue was dissolved in CH2CI2, washed with
water,
zo dried over Na2S04 and evaporated. The residue was chromatographed on
silica, eluting
with heptane:isopropyl ether( 1:2) to give 2.0 g (83%) of the desired product.
~H-NMR (300 MHz, CDCI3): 8 1.45 (t, 3H), 2.4 (s, 6H), 2.7 (s) 3H), 4.45 (q,
2H), 5.2 (s,
2H), 6.7-6.9 (m, 4H), 9.0 (d, 2H)
2s
Example 2.18
Synthesis of 8-amino-6-bromo-3-carboethoxy-2-methylimidazo(1,2-a]pyridine
so A mixture of 2,3-diamino-5-bromopyridine (2.5 g, 13.31 mmol) and ethyl 2-
chloroacetoacetate (2.41 g, 14.64 mmol) in 35 ml abs. Ethanol was refluxed for
14 h. The
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
53
ethanol was evaporated under reduced pressure. The residue was dissolved in
methylene
chloride and neutralized by aqueous NaHCOg. The organic layer was separated,
dried and
evaporated in vacuo. The residue was purified by column chromatography on
silica gel
with methylene chloride:methanol { 100:3.5) as eluent to give I .55 g (39%) of
the title
s compound.
1H-NMR (300 MHz, CDCl3): 8 8.9 (s, 1H)) 6.65 (s, IH), 4.6 (bs) 2H), 4.4 (q,
2H), 2.65 (s)
3H), 1.4 (t, 3H).
to Example 2.19
Synthesis of 6-bromo-3-carboethoxy-8-(2,6-dimethyl-4 fluorobenzylamino)-2-
methylimidazo jl , 2-aJpyridine
is A mixture of 8-amino-6-bromo-3-carboethoxy-2-methylimidazo[ 1,2-aJpyridine
(2.06 g)
6.91 mmol), 2,6-dimethyl-4-fluorobenzylbromide ( i .OS g, 4.48 mmol), sodium
iodide (0.45
g), sodium carbonate (2.2 g) and acetone (40 ml) was refluxed for 22 h. The
reaction
mixture was filtered. The filtered material was washed with CH2C12. The
methylene
chloride solution was washed with water, dried and evaporated in vacuo. The
residue was
2o suspended in ethanoUether and filtered to give 1.15 g (56%) of the title
compound.
~ H-NMR (300 MHz) CDC13): 8 8.85 (s) I H)) 6.8 (d, 2H), 6.55 (s) 1 H), 4.9 (t)
1 H), 4.4 (q,
2H), 4.3 (d, 2H)) 2.6 (s) 3H), 2.4 (s, 6H), 1.45 (t, 3H).
is Example 2.20
Synthesis of 3-(2,6-dimethylbenryloxy)-5-methyl-2-nitropyridine
To 0.52 g (8.02 mmol) of 87% KOH and 0.15 g q-iodide in 6 ml 95% ethanol was
added a
so solution of 3-hydroxy-5-methyl-2-nitropyridine ( 1.2 g, 7.79 mmol) in 25 ml
of ethanol. To
the resulting suspension of the potassium salt was added dropwise a solution
of 2,6-
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
54
dimethyl benzylchloride ( 1.24 g) 8.02 mmol) in 13 ml of ethanol. The reaction
mixture was
refluxed for 1 h. More 87% KOH (0.16 g) and 2,6-dimethylbenzylchloride (0.38
g) were
added. The reaction mixture was refluxed for additional 70 min. The mixture
was filtered
and the inorganic salts were washed with ethanol and methylene chloride. The
organic
s layer was evaporated in vacuo. The residue was dissolved in methylene
chloride, washed
with aqueous NaHC03, dried and evaporated in vacuo. The residue was suspended
in
ether/isopropanol and filtered to give I .72 g (81 %) of the title compound.
1H-NMR (500 MHz, CDC13): b 7.94 (s, 1H), 7.46 (s, 1H), 7.19 (t, 1H), 7.08 (d,
2H), 5.18
to (s, 2H), 2.47 (s, 3H), 2.4 (s, 6H).
Example 2.21
Synthesis of 2-amino-3-(2, 6-dimethylbenzyloxy)-S-methylpyridine
A mixture of 3-(2,6-dimethylbenzyloxy}-5-methyl-2-nitropyridine ( 1.9 g, 6.99
mmol), iron
powder (6.4 g), concentrated HCl (0.1 S ml), water ( 1.5 ml) and 95% ethanol
(35 ml) was
refluxed for 1.0 h. The reaction mixture was filtered over celite and the
solvent was
removed under reduced pressure. The residue was purified by column
chromatography on
2o silica gel, using methylene chloride:methanol ( I00:4) as eluent to give
1.56 g (92 %) of the
title compound.
i H-NMR (500 MHz, CDC13): 8 7.57 s, 1 H), 7.2 (t, 1 H)) 7.09 (d, 2H), 6.95 (s,
1 H)) 5.02 (s)
2H), 4.45 (bs, 2H)) 2.4 (s, 6H), 2.25 (s, 3H).
Example 2.22
Synthesis of 3-carboethoxy-2,6-dimethyl-8-(2,b-dimetl>:ylbenzyloxy)imidazo(1,2-
ajpyridine
so A mixture of 2-amino-3-(2,6-dimethylbenzyloxy)-5-methylpyridine ( 1.0 g)
4.13 mmol) and
ethyl 2-chloroacetoacetate (0.79 g) 4.55 mmol) in 20 ml abs. ethanol was
refluxed for 19 h.
CA 02280008 1999-08-03
- WO 98/37080 PCT/SE98/00275
More ethyl 2-chloroacetoacetate (0.25 g) was added. The reaction mixture was
refluxed for
additional 23 h. The solvent was evaporated in vacuo and the residue was
dissolved in
methylene chloride and washed with aqueous NaHC03. The organic layer was dried
and
' evaporated under reduced pressure. The crude product was purified by column
s chromatography on silica gel) using methylene chloride:ethyl acetate {
100:10) as eluent to
give 0.68 g (47%) of the title compound.
1 H-NMR (500 MHz, CDCl3): b 8.8 (s, 1 H)) 7.15 (t, 1 H)) 7.04 (d, 2H)) 6.71
(s) 1 H), 5.22 (s)
2H)) 4.41 (q, 2H), 2.67 (s, 3H), 2.41 (s, 6H)) 2.39 (s, 3H), 1.42 (t) 3H).
io
Example 2.23
Synthesis of 3-carboethoxy-8-(2,6-dimethyl-4 fluoro-benzylamino)-2-
methylimidazo(1,2-
a]pyridine
~s
A stirred mixture of ( 1.0 g) 4.7 mmol) 8-amino-3-carboethoxy-2-
methylimidazo( 1,2-
a]pyridine ( 1.2 g, 5.7 mmol) 2,6-dimethyl-4-fluorobenzylbromide, ( 1.0 g) 7.5
mmol)
potassium carbonate and (0.1 g) sodium iodide in 15 ml acetonitrile was
refluxed over
night. After evaporation of the solvent under reduced pressure the residue was
dissolved in
Zo dichloromethane and washed with water, the organic layer was separated
dried over sodium
sulfate and evaporated under reduced pressure. The residue was purified by
column
chromatography on silica gel, eluent petroleum ether (40-60) : isopropyl ether
7:3 to give
1.2 g, (75%) of the title compound.
is 1 H-NMR (300, MHz, CDCI3): 8 1.45 (t, 3H), 2.35 (s, 6H), 2.65 (s, 3H), 4.40
(d, 2H)) 4.40
(q) 2H), 4.85 (t, 1 H), 6.40 (d, 1 H)) 6.75 (d, 2H), 6.85 (t, 1 H), 8.70 (d, 1
H)
Example 2.24
3o Synthesis of 2-ethyl -4 fluoro-6-rnethylbenzylbromide
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
56
A mixture of 3-ethyl-1-fluoro-5-methylbenzene (1.1 g, 0.008 mol),
paraformaldehyde (1.5
g, 0.05 mol), hydrobromic acid (4.1 ml 0.017 mol) (4.1 M in acetic acid) and
acetic acid
(2,5 ml) was stirred at ambient temperature for 40 h.. To the mixture were
water and
petroleum ether (40-60) added and the organic layer was separated) washed with
water,
dried over anhydrous sodium sulfate and evaporated carefully under reduced
pressure. The
desired product was obtain as a yellow oil (1.3 g, 72%).
i H-NMR (300 MHz, CDCIg): 8 1.2 (t) 3H)) 2.35 (s, 3H), 2.7 (q, 2H), 4.50 (s,
2H), 6.7-6.85
io (m, 2H)
Example 2.25
Synthesis of 3-carboethoxy-2,6-dimethyl-8-(2-ethyl-4 fluoro-6-
is methylbenzylamino)imidazo(1,2-aJpyridine
A stirred mixture of (0.7g) 3.0 mmol) 8-amino-3-carboethoxy-2,6-
dimethylimidazo[ 1,2-
a]pyridine, (0.8 g) 3.5 mmol) 2-ethyl-4-fluoro-6-methylbenzylbromide) (0.7 g)
4.8 mmol)
potassium carbonate and (0.1 g) sodium iodide in 15 ml acetonitrile was
refluxed over
Zo night. After evaporation of the solvent under reduced pressure the residue
was dissolved in
dichloromethane and washed with water) the organic layer was separated dried
over sodium
sulfate and evaporated under reduced pressure. The residue was purified by
column
chromatography on silica geI) eluent petroleum ether (40-60) : isopropyl ether
7:3 to give
0.4 g, (35%) of the title compound.
2s
tH-NMR (300 MHz, CDCl3): 8 1.25 (t) 3H), 1.45 (t, 3H), 2.4 (s, 6H}, 2.65 (s,
3H), 2.75 (q,
2H), 4.3 (d, 2H), 4.4 (q) 2H), 4.75 (bs, 1H), 6.3 (s, IH)) 6.75-6.85 (m, 2H))
8.5 (s) IH).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
57
Example 2.26
Synthesis of 3-carboethoxy-8-(2-ethyl-6-methylbenzyloxy)-2-methylimidazojl,2-
ajpyridine
s A stirred mixture of 3-carboethoxy-8-hydroxy-2-methylimidazo[ 1,2-a]pyridine
(0.92 g, 4.2
mmol), (0.7 g, 4.2 mmol) 2-ethyl-6-methylbenzylchloride (0.7 g, 4.2 mmol),
sodium
carbonate ( 1.0 g, 9.4 rnmol) and a catalytic amount of potassium iodide in
acetonitrile (40
ml) was refluxed for 4 h.. After filtration and evaporation of the solvent
under reduced
pressure the residue was purified by column chromatography on silica gel using
methylene
io chloride: ethylacetate as eluent to give 1.0 g, (68%) of the title
compound.
t H-NMR (300 MHz, CDCl3): 8 1.2 (t, 3H), 1.4 (t, 3H)) 2.4 (s, 3H)) 2.65 (s)
3H)) 2.75 (q,
2H), 4.4 (q, 2H)) 5.25 (s, 2H), 6.85-6.9 (m, 2H), 7.05-7.25
(m, 3H), 8.95 (dd, 1H).
~s
Example 2.27
Synthesis of 3-ethyl-1-tluoro-5-methylbenzene
2o Methyllithium (40 ml. 64 mlnol) was added dropwise at 0°C to a
slurry of copper(I)iodide
(6.42 g) 33.6 mmol) in diethyl ether (20 ml). After being stirred at
0°C for 30 minutes) the
clear colorless homogeneous cuprate solution was cooled to -78°C where
3-bromomethyl-
1-fluoro-5-methylbenzene (5.15 g, 25.4 mmol) in 10 ml diethyl ether was added.
The
temperature was allowed to rise slowly. The reaction was quenched at -
50°C with
is NH4CI/NH3-buffer (50 ml). Extraction with diethyl ether (3 x 50 ml), brine
( 1 x 100 ml).
The organic layer was dried over MgS04) filtered and the solvents were removed
to yield
3.3 g (94 %) of the title compound.
tH-NMR (500 MHz) CDCl3): d 1.22 (t, 3H)) 2.32 (s) 3H), 2.60 (q, 2H), 6.69 (d)
2H), 6.78
30 (s, 1H).
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
58
BIOLOGICAL TESTS
s 1. In vitro experiments
Acid secretion inhibition in isolated rabbit gastric glands
Inhibiting effect on acid secretion in vitro in isolated rabbit gastric glands
was measured as
io described by Berglindh et al. (1976) Acta Physiol. Scand. 97, 401-414.
Determination of H+,K+-ATPase activity
Preparation of gastric membrane vesicles: Gastric membrane vesicles containing
H+,K+-
~s ATPase were prepared from hog stomachs as previously described by Saccomani
et al.
(1977) Biochim. Biophys. Acta 465) 311-330.
Permeable vesicles: The membrane fraction was diluted with 1 mM PIPESrTris, pH
7.4, to
obtain a 1 % sucrose concentration, homogenized and centrifuged at 100,000 x g
for 2
2o hours. The resulting pellet was suspended in water and lyophilized twice.
Determination of H+,K+-ATPase activity: Permeable membrane vesicles (2.5-5 pg)
were
incubated for 15 min at 37°C in 18 mM PIPES/Tris buffer, pH 7.4,
containing 2 mM
MgCl2, 10 mM KCl and 2 mM ATP. The ATPase activity was estimated as release of
2s inorganic phosphate from ATP, as described by LeBel et al. ( 1978) Anal.
Biochem. 85) 86-
89.
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
59
2. In vivo experiments
Inhibiting effect on acid secretion in female rats
s Female rats of the Sprague-Dawly strain are used. They are equipped with
cannulated
fistulae in the stomach (lumen) and the upper part of the duodenum, for
collection of
gastric secretions and administration of test substances, respectively. A
recovery period of
14 days after surgery is allowed before testing commenced.
io Before secretory tests, the animals are deprived of food but not water for
20 h. The stomach
is repeatedly washed through the gastric cannula with tap water
(+37°C), and 6 ml Ringer-
Glucose given subcutaneously. Acid secretion is stimulated with infusion
during 2.5-4 h
( 1.2 ml/h, subcutaneously) of pentagastrin and carbachol (20 and 110
nmol/kg~h,
respectively)) during which time gastric secretions are collected in 30-min
fractions. Test
~s substances or vehicle are given either at 60 min after starting the
stimulation (intravenous
and intraduodenal dosing) 1 ml/icg), or 2 h before starting the stimulation
(oral dosing, 5
ml/lcg) gastric cannula closed). The time interval between dosing and
stimulation may be
increased in order to study the duration of action. Gastric juice samples are
titrated to pH
7.0 with NaOH, 0.1 M, and acid output calculated as the product of titrant
volume and
zo concentration.
Further calculations are based on group mean responses from 4-6 rats. In the
case of
administration during stimulation; the acid output during the periods after
administration of
test substance or vehicle are expressed as fractional responses, setting the
acid output in the
zs 30-min period preceding administration to 1Ø Percentage inhibition is
calculated from the
fractional responses elicited by test compound and vehicle. In the case of
administration
before stimulation; percentage inhibition is calculated directly from acid
output recorded
after test compound and vehicle.
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
Bioavailability in rat
Adult rats of the Sprague-Dawley strain are used. One to three days prior to
the
experiments all rats are prepared by cannulation of the left carotid artery
under anaesthesia.
The rats used for intravenous experiments are also cannulated in the jugular
vein (Popovic
( 1960) J. Appl. Physiol. 15, 727-728). The cannulas are exteriorized at the
nape of the
neck.
Blood samples (0.1 - 0.4 g) are drawn repeatedly from the carotid artery at
intervals up to
io 5.5 hours after given dose. The samples are frozen until analysis of the
test compound.
Bioavailability is assessed by calculating the quotient between the area under
blood/plasma
concentration (AUC) curve following (i) intraduodenal (i.d.) or oral (p.o.)
administration
and (ii) intravenous (i.v.) administration from the rat or the dog,
respectively.
as
The area under the blood concentration vs. time curve, AUC) is determined by
the
logllinear trapezoidal rule and extrapolated to infinity by dividing the last
determined blood
concentration by the elimination rate constant in the terminal phase. The
systemic
bioavailability (F%) following intraduodenal or oral administration is
calculated as
2o F(%) _ ( AUC (p.o. or i.d.) / AUC (i.v.) ) x 100.
Inhibition of gastric acid secretion and bioavailability in the conscious dog.
Labrador retriever or Harrier dogs of either sex are used. They are equipped
with a
~s duodenal fistula for the administration of test compounds or vehicle and a
cannulated
gastric fistula or a Heidenhaim-pouch for the collection of gastric secretion.
Before secretory tests the animals are fasted for about 18 h but water is
freely allowed.
Gastric acid secretion is stimulated for up to 6.5 h infusion of histamine
dihydrochloride
30 ( 12 ml/h) at a dose producing about 80% of the individual maximal
secretory response, and
gastric juice collected in consecutive 30-min fractions. Test substance or
vehicle is given
CA 02280008 1999-08-03
WO 98/37080 PCT/SE98/00275
61
orally, i.d. or i.v., 1 or 1.5 h after starting the histamine infusion, in a
volume of 0.5 ml/kg
body weight. In the case of oral administration, it should be pointed out that
the test
compound is administered to the acid secreting main stomach of the Heidenham-
pouch
dog.
s
The acidity of the gastric juice samples are determined by titration to pH
7.0) and the acid
output calculated. The acid output in the collection periods after
administration of test
substance or vehicle are expressed as fractional responses, setting the acid
output in the
fraction preceding administration to 1Ø Percentage inhibition is calculated
from fractional
io responses elicited by test compound and vehicle.
Blood samples for the analysis of test compound concentration in plasma are
taken at
intervals up to 4 h after dosing. Plasma is separated and frozen within 30 min
after
collection and later analyzed. The systemic bioavailability (F%) after oral or
i.d.
is administration is calculated as described above in the rat model.
